© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Scilex Holding Company (SCLX) stock declined over -10.07%, trading at $6.61 on NASDAQ, down from the previous close of $7.35. The stock opened at $7.26, fluctuating between $6.60 and $7.28 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 24, 2026 | 7.26 | 7.28 | 6.60 | 6.61 | 67.27K |
| Mar 23, 2026 | 7.33 | 7.69 | 7.18 | 7.35 | 33.42K |
| Mar 20, 2026 | 7.90 | 7.90 | 7.28 | 7.52 | 28.98K |
| Mar 19, 2026 | 7.80 | 8.10 | 7.51 | 7.80 | 27.95K |
| Mar 18, 2026 | 8.04 | 8.14 | 7.72 | 7.72 | 29.92K |
| Mar 17, 2026 | 8.33 | 8.73 | 8.03 | 8.15 | 34.97K |
| Mar 16, 2026 | 8.40 | 8.71 | 7.99 | 8.43 | 27.11K |
| Mar 13, 2026 | 8.72 | 9.01 | 8.15 | 8.28 | 31.82K |
| Mar 12, 2026 | 9.05 | 9.19 | 8.69 | 8.81 | 34.35K |
| Mar 11, 2026 | 8.54 | 9.77 | 8.37 | 9.23 | 50.71K |
| Mar 10, 2026 | 8.59 | 8.79 | 8.32 | 8.65 | 19.67K |
| Mar 09, 2026 | 8.31 | 8.62 | 8.00 | 8.58 | 15.75K |
| Mar 06, 2026 | 8.26 | 8.48 | 7.98 | 8.48 | 22.53K |
| Mar 03, 2026 | 7.85 | 9.00 | 7.69 | 8.97 | 122.93K |
| Mar 02, 2026 | 7.96 | 8.22 | 7.90 | 8.09 | 17.2K |
| Feb 27, 2026 | 8.12 | 8.21 | 7.74 | 8.21 | 33.27K |
| Feb 26, 2026 | 8.20 | 8.45 | 7.86 | 8.12 | 25K |
| Feb 25, 2026 | 8.13 | 8.33 | 7.80 | 8.23 | 26.59K |
| Feb 24, 2026 | 7.80 | 8.25 | 7.80 | 8.16 | 20.83K |
| Feb 23, 2026 | 8.01 | 8.33 | 7.68 | 7.85 | 26.44K |
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Employees | 115 |
| Beta | 1.37 |
| Sales or Revenue | $46.74M |
| 5Y Sales Change% | 1.407% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |